Fulcrum Therapeutics, Inc. $FULC Holdings Boosted by Vanguard Personalized Indexing Management LLC

Vanguard Personalized Indexing Management LLC lifted its holdings in Fulcrum Therapeutics, Inc. (NASDAQ:FULC) by 26.1% in the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 12,943 shares of the company’s stock after buying an additional 2,677 shares during the period. Vanguard Personalized Indexing Management LLC’s holdings in Fulcrum Therapeutics were worth $89,000 as of its most recent SEC filing.

Several other large investors have also recently bought and sold shares of the business. Y Intercept Hong Kong Ltd purchased a new position in Fulcrum Therapeutics during the 1st quarter valued at about $92,000. XTX Topco Ltd acquired a new position in Fulcrum Therapeutics in the 1st quarter valued at approximately $144,000. Invesco Ltd. increased its stake in Fulcrum Therapeutics by 186.1% in the 1st quarter. Invesco Ltd. now owns 85,767 shares of the company’s stock valued at $247,000 after buying an additional 55,791 shares during the period. Virtu Financial LLC purchased a new stake in Fulcrum Therapeutics in the 1st quarter worth approximately $39,000. Finally, Nuveen LLC acquired a new stake in shares of Fulcrum Therapeutics during the 1st quarter valued at $441,000. 89.83% of the stock is owned by institutional investors and hedge funds.

Fulcrum Therapeutics Stock Performance

NASDAQ FULC opened at $9.22 on Monday. The stock has a 50-day simple moving average of $7.94 and a 200 day simple moving average of $6.82. Fulcrum Therapeutics, Inc. has a twelve month low of $2.32 and a twelve month high of $9.89. The stock has a market capitalization of $498.71 million, a PE ratio of -7.56 and a beta of 2.93.

Fulcrum Therapeutics (NASDAQ:FULC) last announced its earnings results on Tuesday, July 29th. The company reported ($0.28) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.29) by $0.01. As a group, equities research analysts forecast that Fulcrum Therapeutics, Inc. will post -0.16 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities analysts recently commented on the company. Weiss Ratings restated a “sell (d-)” rating on shares of Fulcrum Therapeutics in a report on Saturday. Wall Street Zen raised shares of Fulcrum Therapeutics from a “sell” rating to a “hold” rating in a research note on Friday, September 26th. Leerink Partners set a $20.00 target price on shares of Fulcrum Therapeutics and gave the stock an “outperform” rating in a research report on Tuesday, October 21st. HC Wainwright reaffirmed a “buy” rating and issued a $12.00 price target on shares of Fulcrum Therapeutics in a research report on Monday, October 20th. Finally, Royal Bank Of Canada upped their price target on Fulcrum Therapeutics from $4.00 to $5.00 and gave the stock a “sector perform” rating in a research note on Wednesday, July 30th. One analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $11.20.

About Fulcrum Therapeutics

Fulcrum Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial.